OCR Related Analyst Ratings
-
Barclays Maintains an 'Equalweight' on Omnicare (OCR); New CEO, Come on Down
-
Canaccord Genuity Morning Coffee on Johnson & Johnson (JNJ): Big Legal Bills To Get Bigger
-
Omnicare (OCR) Shares Down 7+%; JPMorgan Says Buy the Dip
-
UBS maintains a 'Neutral' on PharMerica (PMC); Q1 Preview; Is There A Hangover From OCR’s Hostile Takeover Attempt?
-
Credit Suisse Upgrades Omnicare (OCR) to Outperform
-
Barclays Maintains a 'Equalweight' on Omnicare (OCR); Thoughts on the Analyst Day - 'A Big Boy Company'
-
Cowen Starts Omnicare (OCR) at Outperform
-
UPDATE - Barclays Upgraded Omnicare (OCR) to Equalweight; Looking Forward to 2012
-
Barclays Upgrades Omnicare (OCR) to Equalweight
-
UBS Maintains a 'Neutral' on Omnicare (OCR); 2nd Draft of AMP-based FUL Just Released
-
Leerink Swann maintains an 'Outperform' on Omnicare (OCR); Threat from CMS Proposal Appears Overstated
-
Omnicare (OCR), PharMerica (PMC) Shares Sink as CMS Proposes New Rules; JPMorgan Defends Omnicare
-
UBS Maintains a 'Neutral' on PharMerica (PMC); Raising Target On Acquisition Prospects
-
Barclays on Health Care Facilities: PMC Rejects OCR's Bid. Now What?
-
Barclays Maintains an 'Underweight' on Omnicare (OCR); June Quarter Review - After the Call
-
Susquehanna Downgrades Omnicare (OCR) to Neutral
-
Barclays Maintains an 'Underweight' on Omnicare (OCR); 'New and Improved' Senior Management Meetings Review
-
Barclays Maintains an 'Underweight' on Omnicare (OCR); Updating Estimates and 1Q11 Review
-
Barclays Maintains an 'Underweight' on Omnicare (OCR); Looking Forward to 2012
-
Goldman Raises Price Target on Omnicare (OCR) as Good News Comes
-
UPDATE - UBS Downgrades Omnicare (OCR) to Neutral; Moving To The Sidelines Post +25% Rally
-
UBS Downgrades Omnicare (OCR) to Neutral
-
UBS Maintains a 'Neutral' Rating on PharMerica (PMC); Any New Developments? No Sense That Bed Attrition Will Subisde
-
Barclays Maintains an 'Equalweight' Rating on Walgreen Co. (WAG); August Sales Review
-
Barclays Downgrades Institutional Pharmacy Companies (OCR & PMC)
-
Moody's Affirms Omnicare (OCR) Ratings; Outlook Lowered to Negative
-
UBS Maintains a 'Neutral' on PharMerica (PMC); Trends Getting Worse
-
UBS Maintains a 'Buy' on Omnicare (OCR); After the Call: Shaking Things Up
-
Gabelli & Co Downgrades Omnicare (OCR) to 'Hold'
-
Credit Suisse Downgrades Omnicare (OCR) to Neutral
-
Susquehanna Initiates Coverage on Omnicare (OCR) with a Positive; Represents an Interesting Opportunity
-
UBS Upgrades Omnicare (OCR); Court Order Blocking FUL = Buy OCR
-
UBS Upgrades Omnicare (OCR) to Buy
-
UBS Maintains a 'Neutral' on Omnicare (OCR); Raises PT & Estimates
-
UBS Starts Numerous Healthcare Stocks: CAH, MCK, ESRX at Buy, PMC, OCR at Neutral
-
Thomas Weisel Starts 9 Healthcare Stocks: PSYS, EMS, HLS, OCR at Overweight, LNCR, MD, PMC, RHB, IPCM at Market Weight
-
RBC Capital Initiates Coverage on Several Healthcare Stocks
-
Barclays Capital Upgrades Omnicare Inc. (OCR) to Overweight
-
Soleil Securities Upgrades Omnicare (OCR) to Buy
-
Morgan Stanley Upgrades Omnicare (OCR) to Equalweight
-
JPMorgan Selects 26 Small, Mid-Cap Stocks That Can Outperform
-
Soleil Securities Initiates Coverage on Omnicare (OCR) with a Hold
-
Buckingham Research Downgrades to Omnicare (OCR) Neutral
-
Jefferies Upgrades Omnicare (OCR) to Buy
-
Matrix USA Rating Changes 7/11
-
Credit Suisse Starts Omnicare Inc. (OCR) at Outperform
-
Leerink Swann Initiates Coverage on Omnicare (OCR) with a Market Perform
-
Oppenheimer Upgrades Omnicare (OCR) to Outperform
-
Buckingham Research Upgrades Omnicare (OCR) to Accumulate
-
Oppenheimer Downgrades Omnicare (OCR) to Perform
Back to OCR Stock Lookup
